Using it off-label for weight loss would require much higher doses than it is currently approved for and it would not be cost effective
But the study is on par with what we see clinically in many people who stop GLP-1 medications, says Chika Anekwe, an obesity medicine physician at Massachusetts General Hospital Weight Center, who was not involved in the research
The SUSTAIN-6 trial showed semaglutide specifically reduced non-fatal stroke risk by 39% 17
This treatment typically involves a combination of techniques, such as non-invasive fat reduction technologies (e.g., radiofrequency, ultrasound), diode, and other body contouring procedures
Whether youre struggling with obesity-related health issues or seeking a transformative weight loss solution, Dr
These provide the most radical and enduring solutions